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A B S T R A C T
Background
Quitting smoking improves prognosis after a cardiac event, but many patients continue to smoke, and improved cessation aids are
urgently required.
Objectives
To assess the effectiveness of psychosocial interventions such as behavioural therapeutic intervention, telephone support and self-help
interventions in helping people with coronary heart disease (CHD) to quit smoking.
Search strategy
The Cochrane Central Register of Controlled Trials (issue 2 2003), MEDLINE, EMBASE, PsycINFO and PSYNDEX were searched
from the start of the database to August 2003. Results were supplemented by cross-checking references, and handsearches in selected
journals and systematic reviews.
Selection criteria
Randomised controlled studies (RCTs) in patients with CHD with a minimum follow-up of 6 months. After initial selection of the
studies three trials with methodological flaws (e.g. high drop out) were excluded.
Data collection and analysis
Abstinence rates were computed according to an intention to treat analysis if possible, or if not on follow-up results only.
Main results
We found 16 RCTs meeting inclusion criteria. Interventions consist of behavioural therapeutic approaches, telephone support and self-
help material and were either focused on smoking cessation alone or addressed several risk factors. The trials mostly included older male
patients with CHD, predominantly myocardial infarction. Overall there was a positive effect of interventions on abstinence after 6 to
12 months (odds ratio (OR) 1.66, 95% confidence interval (CI) 1.25 to 2.22), but substantial heterogeneity between trials. Studies
with validated assessment of smoking status at follow-up had lower efficacy (OR 1.44, 95% CI 0.99 to 2.11) than non-validated trials
(OR 1.92, 95% CI 1.26 to 2.93). Studies were clustered by intervention strategy and intensity of the intervention. Clustering reduced
heterogeneity, although many trials used more than one type of intervention. The ORs for different strategies were similar (behavioural
therapies OR 1.69, 95% CI 1.33 to 2.14; telephone support OR 1.58, 95% CI 1.28 to 1.97; self-help OR 1.48, 95% CI 1.11 to 1.96).
More intense interventions showed increased quit rates (OR 1.98, 95% CI 1.49 to 2.65) whereas brief interventions did not appear
effective (OR 0.92, 95% CI 0.70 to 1.22). Two trials had longer term follow-up, and did not show any benefits after 5 years.
Authors’ conclusions
Psychosocial smoking cessation interventions are effective in promoting abstinence at 1 year, provided they are of sufficient duration.
Further studies, with longer follow-up, should compare different psychosocial intervention strategies, or the addition of a psychosocial
intervention strategy to pharmacological therapy (e.g. nicotine replacement therapy) compared with pharmacological treatment alone.
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P L A I N L A N G U A G E S U M M A R Y
Psychosocial smoking cessation interventions such as behavioural counselling, telephone support and self-help interventions are effective
in helping people with coronary heart disease stop smoking. Smoking is a risk factor for coronary heart disease and stopping smoking
lowers that risk. Psychosocial smoking cessation interventions such as behavioural therapy, telephone support and self-help materials
are effective in helping coronary heart disease patients to stop smoking, if they are provided for over 1month. We found evidence that
psychosocial interventions increased quit rates after 6 months. Most trials used a mixture of different intervention strategies, therefore
no single strategy showed superior efficacy.
B A C K G R O U N D
Smoking is a major risk factor for coronary heart disease (CHD).
Compared to non-smokers the odds ratio (OR) for myocardial
infarction is about 2.5, and for cardiovascular disorders overall
the OR is about 2 (Cook 1986; Jacobs 1999; Kawachi 1994; Keil
1998; Njolstad 1996; Nyboe 1991; Prescott 1998; Shaper 1985;
Tunstall-Pedoe 1997; Willett 1987; Woodward 1999). Further-
more after a cardiac event smokers are two times more likely to
get restenosis or to die from a cardiovascular disease (Cullen 1997;
Fulton 1997; Kawachi 1993; Kawachi 1994; Kuller 1991; Luoto
1998; Tverdal 1993; Willett 1987). A recent systematic review
in patients with CHD estimated a reduction in mortality risk of
36% in 3-5 years after quitting smoking (Critchley 2003). Non-
fatal myocardial infarction also occurs less often in smokers who
quit after their first cardiac event (OR 0.62, 95% CI 0.46 to 0.83)
(Barth 2007). However, many smokers do not quit, even after a
CHD diagnosis (Critchley 2003), and it is critical to summarise
available evidence regarding the effectiveness of different interven-
tion strategies for smoking cessation in this patient group.
Several intervention strategies in healthy people have shown en-
couraging results in systematic reviews. Simple, brief advice from
a physician to quit can increase odds of quitting by over 70% (OR
1.74, 95% CI 1.48 to 2.05) (Lancaster 2004) compared with no
intervention. Group behaviour therapy has been shown to double
success (OR 1.97, 95% CI 1.57 to 2.48) (Stead 2005) compared
with self-help interventions and is more effective than no inter-
vention. One systematic review found that more intense interven-
tions did not improve abstinence rates (Lancaster 2005a), how-
ever, another review found that telephone counselling was more
effective than less intense interventions such as self-help (Stead
2006). Self-help interventions may increase quit rates compared
with no intervention but the effect is likely to be small (Lancaster
2005b), and there is no evidence they have any additional effects
in combination with counselling.
Rigotti has demonstrated the efficacy of smoking cessation in-
terventions for hospitalised patients and stressed the importance
of at least one follow-up contact to maintain abstinence (Rigotti
2007). Another review showed that nursing interventions resulted
in improved abstinence rates compared with no intervention (Rice
2004), and showed comparable results in hospitalized and healthy
people. These various treatment strategies can be summarised as
psychosocial interventions and can be differentiated from psy-
chopharmacological or substance replacement treatment strate-
gies (e.g. antidepressants, nicotine replacement). A recent review
in patients with chronic obstructive pulmonary disorders did not
find a beneficial effect of psychosocial interventions on smoking
abstinence, but few studies were included (van der Meer 2001). A
recent review of smoking cessation interventions in CHD patients
did not find any benefits. However, this review included only 12
studies, which had been previously included in published system-
atic reviews (Wiggers 2003). Although both psychosocial (n = 10)
and pharmacological interventions (n = 2) were included, litera-
ture searching was not comprehensive. Integration of the studies
was descriptive simply counting positive and negative results and
the review was unable to assess possible dose-response relation-
ships or influence of study quality. For cardiac patients, psychoso-
cial interventions to quit smoking are recommended along with
nicotine replacement therapies and bupropion (ACC/AHA 2002;
DeBacker 2003; Ockene 1997). Yet, there is no clear evidence that
psychosocial interventions in patients with CHD are efficacious,
whether more intense interventions improve quit rates, or which
components of intervention programs result in better abstinence
rates.
O B J E C T I V E S
This review aimed to evaluate psychosocial intervention strategies
for smoking cessation in patients with coronary heart disease, with
four specific objectives.
1. To examine the efficacy of psychosocial interventions for smok-
ing cessation in patients with coronary heart disease in short term
(6 to 12 month follow-up) and long term (more than 12 months).
2. To compare different psychosocial intervention types (e.g. tele-
phone support) to stop smoking in patients with coronary heart
disease.
3. To assess the dose-response relationship: Are brief interventions
as effective as more intense interventions?
4. To examine methodological criteria which may moderate the
efficacy of smoking cessation interventions in patients with coro-
nary heart disease (validation versus self-report of abstinence).
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C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
We included randomised controlled trials studying the efficacy of
psychosocial interventions for smoking cessation in CHDpatients
with an assessment of study outcome at least 6 months after base-
line assessment of smoking status. Acceptable study designs were:
a) psychosocial interventions to no such interventions;
b) psychosocial interventions to other psychosocial interventions;
and
c) psychosocial interventions to the same psychosocial interven-
tions of different intensity.
Types of participants
Patients with CHD - myocardial infarction, coronary artery by-
pass surgery, percutaneous transluminal coronary angioplasty (In-
ternational Classification of Diseases 9 codes 410-414). Studies
including patients with other diseases were accepted, provided at
least 80% of patients had CHD. CHD patients with other co-
morbidities were included if the diagnosis of CHD was proven.
Patients had to be smokers at baseline. Initial smoking status was
assessed either by self-report or by additional validation measures.
Hospital populations with mixed somatic events (for example pul-
monary diseases and cancer) were excluded. Trials were also ex-
cluded if there was not sufficient information available about the
patient’s somatic diagnoses.
Types of intervention
The psychosocial intervention could be provided in two ways;
either as a separate psychosocial intervention with a main focus
on smoking cessation or as a part of a more comprehensive car-
diac rehabilitation programme addressing also other risk factors
also (such as diet). Any psychosocial intervention with the goal
to change smoking behaviour in CHD patients was of interest. If
the intervention strategy was solely based on a pharmacological or
a nicotine replacement approach, the study was excluded. Inter-
ventions could be delivered initially during hospital admission or
after hospital admission to ex-patients. The interventions may be
provided in group or individual settings. Interventions that incor-
porated counselling, support and advice, with or without provi-
sion of written materials were included.
Types of outcome measures
Abstinence by self-report or validated (e.g. carbonmonoxide)mea-
surement at a minimum of 6 months. The outcome is dichoto-
mous (abstinent versus smoking). We did not extract data on the
number of cigarettes smoked per day, as there is little evidence
that smoking reduction alters the risk of future cardiac events or
mortality.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Heart Group methods used in reviews.
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) on The Cochrane Library (issue 2, 2003), EMBASE
(until 1998), MEDLINE (1966-2003), PsycINFO (until week
34, 2003), PSYNDEX (1977-June 2003). No limitations were
set to randomised controlled trials. The search strategy for
CENTRAL on The Cochrane Library is shown below, search
strategies for other databases are in additional tables 1 to 4.
#1 HEART DISEASES (exp MeSH)
#2 CORONARY ARTERY BYPASS (exp MeSH)
#3 angina*
#4 cabg
#5 (coronary near bypass*)
#6 (coronary near disease*)
#7 MYOCARDIAL INFARCTION (exp MeSH)
#8 (myocard* near infarct*)
#9 (heart near infarct*)
#10 chd
#11 (heart next disease*)
#12 (cardiac next disease*)
#13 acs
#14 ami
#15 (cardiac next inpatient*)
#16 (cardiac next patient*)
#17 (heart next patient*)
#18 (heart next inpatient*)
#19 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)
#20 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or
#18)
#21 (#19 or #20)
#22 SMOKING CESSATION (exp MeSH)
#23 (smoking near cessation)
#24 (smoking near cease*)
#25 (smoking near quit*)
#26 antismoking
#27 (anti next smoking)
#28 (smoking near giv*)
#29 (smoking near stop*)
#30 (#22 or #23 or #24 or #25 or #26 or #27 or #28 or #29)
#31 (#21 and #30)
Additionally we searched all databases on The Cochrane Library
for reviews on smoking cessation
Handsearching
We searched for trials included in other reviews (Lancaster
2005a; Rigotti 2007; Stead 2005; Stead 2006; Wiggers 2003)
and hand-searched relevant journals from 1998 to 2003 (Annals
of Internal Medicine, Archives of Internal Medicine, British
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Medical Journal, Psychology and Health, Health Psychology,
Tobacco Control). Additionally we looked through the reference
lists of the initially identified trials. We asked experts from the
German Statusconference on Psychocardiology for information
on other trials (see http://portal.uni-freiburg.de/psychokardio/).
We did not search for ongoing studies, abstracts, and unpublished
studies.
M E T H O D S O F T H E R E V I E W
Data extraction and coding
Data were independently extracted by two people (JBA and
Corina Güthlin). Data on setting, CHD diagnosis or procedure,
number of subjects, sex, age, and length of follow up were
extracted. Five types of interventions were coded; behavioural
therapeutic approaches (BT); phone support (Ph); additional self-
help intervention (SH); multi-risk factor interventions (MR);
specific interventions for smoking cessation (see Charactersitics of
included studies table).
Treatment duration
We assessed duration of treatment as in another review (Rigotti
2007) and coded this as follows:
1) Single initial contact lasting <= 1 hour, no follow-up support;
2) One or more contacts in total > 1 hour, no follow-up support;
3) Any initial contact plus follow-up <=1 month;
4) Any initial contact plus follow-up > 1 month and <= 6 month;
and
5) Any initial contact plus follow-up > 6 month.
Methodological quality
We coded biochemical validation of smoking status as 0=no and
1=yes; this validated assessment of abstinence was a very relevant
methodological aspect of included studies.
Quality of randomisation and allocation concealment was not
coded because of lack of data in most of the trials.
Data analysis
We analysed data on both an intention-to-treat (ITT) and a
follow-up basis. A conservative model classified persons without
information about smoking status at follow-up as smokers (ITT
analysis). A second model included only participants with follow-
up information on smoking status. The latter model results in
higher rates of abstinence in experimental and control group
(termed ’optimistic model’). We present data of the conservative
analysis (ITT) in preference, and only used data from the
optimistic model if the ITT analysis was not possible. As a
sensitivity analysis, we performed meta-analysis only including
those trials where we could calculate the more conservative ITT
analysis. We performed three sub-group analyses:
• Trialswith validated smoking status at follow-upwere compared
to non-validated trials.
• Trials grouped by type of intervention.
• Trials with a treatment duration of less than 1 month versus
studies with an intervention of 1 month or more.
Odds ratios with 95% confidence intervals were calculated for
the pooled estimates. An OR > 1 indicates superiority of the
intervention group over usual care and vice versa. Heterogeneity
was assessed by examining forest plots of trials, by calculating
chi squared heterogeneity test, and I² statistics. The chi squared
value tests for statistically significant heterogeneity between trials;
higher I² values indicate greater variability between trials than
would be expected by chance alone (range 0-100%) (Higgins
2003). A random-effects model for pooling the studies was
employed because of expected heterogeneity in the primary studies
(DerSimonian and Laird method) (Deeks 1999). Significant chi
squared values indicate heterogeneity and therefore the pooled
effect sizes must be interpreted with caution.
D E S C R I P T I O N O F S T U D I E S
The combination of the hits in the databases searched and addi-
tional citations found by scanning references in relevant Cochrane
Reviews, other meta-analyses, and journals resulted in 2012 hits.
After exclusions on the basis of title and abstract, 520 papers were
assessed for inclusion. Of these only 241 studied an intervention
for smoking cessation in cardiac patients. First we excluded all
studies without a randomised controlled design (n = 145). For the
exclusion of other non-relevant studies (n=71) the reason for ex-
clusion is detailed in the characteristics of excluded studies table.
A further three studies were excluded using post hoc exclusion cri-
teria. Feeney 2001 had a drop out > 50% of randomised patients
(OR 48.17 95% CI 6.42 to 361.51); Lisspers 1999 was excluded
because assessment of smoking status wasmade after cardiac proce-
dure had been performed, which risks confounding non-smokers
with those who quit around the time of the procedure (OR 24.20,
95% CI 0.93 to 629.32); and Mitsibounas 1992 reported a statis-
tically significant difference in patient characteristics (age/sex) be-
tween the intervention and control groups at baseline (OR 16.00,
95% CI 2.73 to 93.62). Four papers are awaiting assessment as we
could not access the papers (Becker 2003; Boulay 2001; Enriquez-
Puga 2001; Puente-Silva 1989).
The remaining 18 reports of 16 trials were included in the review
(Allen 1996; Burt 1974; Carlsson 1997; CASIS 1992; DeBusk
1994; Dornelas 2000; Hajek 2002; Heller 1993; Ortigosa 2000;
Quist-Paulsen 2003; Reid 2003; Rigotti 1994; Sivarajan 1983;
Taylor 1990; van Elderen (group); van Elderen (phone)). Seven
studies were carried out in Europe (1 Sweden, 2 United Kingdom,
2 Netherlands, 1 Norway, 1 Spain), seven were from the USA, one
fromAustralia andone fromCanada.The papersweremainly pub-
lished in English (15), one waswritten in Spanish (Ortigosa 2000).
All trials compared a specific smoking cessation intervention with
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a usual care condition, had comparable groups at study entry, had
lower than 50% drop out rates and assessed smoking status before
a cardiac event or procedure. 1323 patients were randomised to the
usual care group and 1354 received a special psychosocial interven-
tion. As expected, 70 to 90% of the patients were male, mean age
was relatively young, 50 to 60 years.The patients suffered predom-
inantly from myocardial infarction or had invasive interventions
(bypass surgery, stent). The intervention strategies employed were
behavioural therapeutic interventions (10 studies), and self-help
programmes (11 studies). Additional phone support was provided
in 11 trials. Nine studies reported interventions aimed specifically
at smoking cessation, seven studies employedmulti-risk strategies.
Behavioural therapeutic interventions were either provided in a
group setting or as individual counselling. The aim was to identify
cues related to smoking, or more generally stress reduction and re-
laxation techniques. Other components included preparation for
relapse or specific motivational techniques based on the transthe-
oretical model (Prochaska 1986) or the strategy of motivational
interviewing (Rollnick 1997). Self-help interventions consisted of
information booklets, audio- or videotapes. Information booklets
which simply described risk factors were not considered self-help
interventions. No studies were available for the comparison of dif-
ferent psychosocial interventions or of psychosocial intervention
with different intensity.
M E T H O D O L O G I C A L Q U A L I T Y
All studies assessed abstinence 12 months after the initial inter-
vention, except two (Heller 1993; Sivarajan 1983), which assessed
abstinence after 6 months. Two trials also provided data on a long-
term follow up after 5 years (CASIS 1992; Rigotti 1994). Seven of
the 16 trials validated self-reported abstinence. In five trials data
for the ’optimistic model’ was reported (n=462), 11 trials provided
sufficient data for an ITT analysis (n=2215). Unfortunately, it was
impossible to extract detailed information on the randomisation
procedure from most of the trials. Only four trials used adequate
allocation concealment (Allen 1996; Dornelas 2000; Hajek 2002;
Reid 2003).
R E S U L T S
Psychosocial smoking cessation interventions were effective in
achieving smoking abstinence in CHD patients, compared with
usual care. In all trials, patients receiving the specific psychosocial
intervention had more than a 60% higher odds of quitting (OR
1.66, 95% CI 1.25 to 2.22). There was considerable heterogene-
ity between individual studies (chi² 42.68; df 15, P < 0.0002, I2
64.9%) (comparison 01 01). Therefore the overall result has to
be interpreted with caution. There were considerable differences
between trials in the proportion of abstinent patients at follow-up:
Taylor 1988 achieved 70% abstinence in the intervention group
but Ortigosa 2000 report the same number of patients abstinent
without intervention. Hajek 2002 report the lowest abstinence
rates in the patients receiving psychosocial intervention (39%) and
Carlsson 1997 report the lowest values for control group patients
(25%).
The pooled ORs suggest that psychosocial interventions can
greatly increase odds of quitting compared with usual care, but
the heterogeneity in the results needed further exploration. The
quality of the trials may partly explain this heterogeneity. Allo-
cation concealment has been shown empirically to influence trial
results (Jüni 2001). Few studies reported adequate allocation con-
cealment. We pooled results for these studies, but results of the
combined effect measure must be interpreted with caution, due to
the limited statistical power (Allen 1996; Dornelas 2000; Hajek
2002; Reid 2003). The non-significant OR of trials using ade-
quate allocation concealment was 1.10 (95% CI 0.75 to 1.60).
The largest trial with adequate allocation concealment was also a
brief intervention (Hajek 2002), which we found not to be effec-
tive (comparison 01 02). The pooled OR for allocation concealed
trials appears lower than for all trials, but due to limited number
of studies it is impossible to assess whether this is due to higher
quality (allocation concealment), or the brevity of the interven-
tion.
Sensitivity analysis of only trials using ITT analysis showed less
benefit than all trials combined, but remained clinical important
(nearly a 50% increase in odds of quitting) and statistically signif-
icant (OR 1.47, 95% CI 1.10 to 1.96) but considerable hetero-
geneity remained (chi² 25.27, df 10, P < 0.005, I2 60.4%) (com-
parison 01 03).
Sub-group analyses
Trials validating smoking status
Trials which validated self-reported smoking status showed lower
quit rates than trials where measurement was not validated. If trials
with validated abstinence are pooled, theOR falls from 1.92 (95%
CI 1.26 to 2.93) for non-validated trials to 1.44 (95% CI 0.99 to
2.11) for validated measures (comparison 02 01).
Types of intervention
We found no clear evidence that any treatment strategy was more
efficacious than others, but heterogeneity was reduced within the
intervention cluster. Behavioral therapeutic interventions showed
a significant effect on abstinence (OR 1.69, 95% CI 1.33 to 2.14)
with lower heterogeneity (I² 23.5%) (comparison 03 01). Tele-
phone support was also effective (OR 1.58, 95% CI 1.28 to 1.97)
and trials reasonably consistent (I² 9.9%) (comparison 03 02).
However, as most behavioural therapy trials also used telephone
support as an intervention strategy, it is difficult to separate the
effects of these two types of interventions. Two trials used solely a
behavioural therapeutic approach without additional phone con-
tacts (Sivarajan 1983; van Elderen (group)). One trial used tele-
phone support without behavioural therapeutic techniques (Or-
tigosa 2000). Interventions using self-helpmaterials showed com-
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parable effectiveness (OR 1.48, 95% CI 1.11 to 1.96) (compar-
ison 03 03). Stratification of trials using self-help materials re-
duced heterogeneity only slightly (I256.2%). We also considered
the specificity of the intervention (smoking cessation alone com-
pared with a multi-risk factor intervention). No difference was
found between multi-risk factor interventions (OR 1.73, 95% CI
1.27 to 2.35) and specific cessation intervention (OR 1.63, 95%
CI 1.08 to 2.46) (comparison 03 04). While the heterogeneity
in specific intervention trials increased (I277.8%) the results of
multi-risk factor intervention trials were statistically homogenous
(I20%).
Duration of the intervention
We found clear evidence that brief interventions (i.e. no follow-
up contact or within 4 weeks after initial intervention) were not
effective (Hajek 2002; Heller 1993; Ortigosa 2000; Rigotti 1994)
(OR 0.92, 95% CI 0.70 to 1.22, I² 0%) (comparison 04 01).
When CHD patients were treated with interventions including
follow-up contacts after the initial period of 1 month, the odds of
quitting increased substantially (OR 1.98, 95%CI 1.49 to 2.65, I²
50.3%) (comparison 04 01). There was less heterogeneity between
trial results when clustered by intensity of the intervention.
Long-term follow-up
We found no evidence for efficacy of smoking cessation interven-
tions in the long-term. Due to high drop-out rates after 5 years, an
analysis for people available at follow-up and an ITT analysis were
performed. Neither the optimistic model (OR 1.32, 95% CI 0.78
to 2.24) nor the ITT analysis (OR 1.23, 95% CI 0.79 to 1.93)
showed superior efficacy to a control group (comparisons 05 01
and 05 02, respectively).
A potential problemwith all systematic reviews is publication bias.
Our literature search was comprehensive, prepared and partly car-
ried out by the Cochrane Heart Group (UK). Additionally, we in-
vestigated publication bias using a funnel plot. The results appear
reasonably symmetric which is an indicator of a publication of the
studies independent of the study result (Figure 01). There may
be a slight tendency for larger trials to show smaller benefits; but
larger studies may have interventions with shorter duration and
hence smaller effect sizes.
D I S C U S S I O N
We found support for the efficacy of smoking cessation interven-
tions with more than 1 month duration, but brief interventions
without some follow-up contact were not effective. We were un-
able to determine theminimum number of contacts needed.More
detailed conclusions about effective intervention strategies are ob-
scured by the fact that amixture of different intervention measures
were included in many trials. Interventions using telephone sup-
port, behavioural therapies, and self-help were all effective. Some
interventions focussed only on smoking cessation, but others ad-
dressed smoking as part of a multiple risk factor intervention pro-
gramme (generally a ’cardiac rehabilitation programme’). There
was no difference in the odds of quitting for multiple risk factor
cardiac rehabilitation programmes, compared with interventions
focussing only on smoking cessation. ’Cardiac rehabilitation’ pro-
grammes may vary in their components, but generally include a
graded exercise programme and may also include advice and sup-
port from a range of health professionals (such as dieticians, be-
havioural change specialists etc). It is difficult to distinguish be-
tween the effects of the smoking cessation component of these pro-
grammes, and the general support and encouragement that may
be given by other health professionals. Some trials employ nico-
tine replacement therapy (NRT) as additional cessation strategies,
which we could not control for. In one trial, more patients in the
psychosocial intervention group received NRT compared to the
usual care group (DeBusk 1994). Other trials did not report use
of NRT.
Our findings are contrary to a recently published review on smok-
ing cessation interventions in CHD patients which found no ben-
efits (Wiggers 2003). The difference may be due to more compre-
hensive literature searching in our review, whereas Wiggers et al
aggregated 12 primary studies listed in already existing Cochrane
reviews. Another difference is the methodology of the reviews.
Wiggers et al counted ’positive’ and ’negative’ results, whereas we
performed a meta-analytic pooling. The important advantage of a
meta-analytic approach is the weighting of studies by sample size
and event rate.
One possible threat to our results might be methodological flaws
in the primary studies. Validation of abstinence was reported in
primary studies, and associated with lower efficacy. The OR of
quitting in validated trials was only of borderline statistical sig-
nificance; however these validated trials also included many with
only a brief intervention. Despite the high validity of self reported
smoking status in the general population (Patrick 1994) the vali-
dation of smoking status should be recommended in efficacy trials
with coronary heart disease patients (Woodward 1992).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
After a cardiac event about 30% to 50% of smokers with CHD
quit without professional help. Additional psychosocial interven-
tions show a superior quitting rate compared to standard care.
Interventions for smoking cessation in CHD patients should last
for more than 1 month. Brief interventions may not be effective.
The overall effect of psychosocial smoking cessation interventions
in CHD patients can be expressed by the number needed to treat
statistics with a figure of 9.7. This means about 10 patients had
to be treated for one person to be abstinent from tobacco after 1
year.
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Implications for research
Trial procedures and quality should be described in more detail,
according to CONSORT guidelines (Begg 1996). Also more de-
tails on the duration and intensity of the intervention (total du-
ration, number of sessions, numbers of pages in leaflets etc) are
needed. The validation of smoking status was not a standard pro-
cedure in the trials as only seven described using any measure of
biochemical validation. Further trials should validate smoking sta-
tus objectively.
Studies comparing different psychosocial interventions or psy-
chosocial intervention of different intensity are lacking. Hence fu-
ture research should focus on the comparison of different smok-
ing cessation strategies in CHD patients (Schmitz 1999). It is still
unclear whether individual counseling or group counseling are
more beneficial in CHD patients. Also recent results of reviews
show limited effects of stage based smoking cessation interven-
tions (Riemsma 2003; vanSluis 2004). More detailed studies will
be useful to identify components of successful intervention strate-
gies. This approach will require fewer studies but with larger sam-
ple sizes to demonstrate relatively small, but clinically important
differences between strategies. Future trials should compare the
additional benefits of combining NRT and psychosocial rehabili-
tation, compared with NRT or psychosocial interventions alone.
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T A B L E S
Characteristics of included studies
Study Allen 1996
Methods OM
Participants 138 women who underwent first-time CABG at a hospital.
IG: 14 smokers
CG: 11 smokers
Interventions Usual care: patient education and instructions for exercise.
Psychosocial intervention: nurse-directed multimodal behavioural program based on social cognitive theory
(videotape, workbook, counselling). Started with discharge from hospital, two updates 1 and 2 months later
(BT, Ph, SH, MR, Intensity 4)
Outcomes Follow-up at 12 months (abstinence self report)
Notes IG: OM = 64.3%
CG: OM = 54.5%
Allocation concealment A – Adequate
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Characteristics of included studies (Continued )
Study Burt 1974
Methods OM
Participants 280 men in a coronary care unit with AMI
IG: 125 smokers
CG: 98 smokers
Interventions Usual care: conventional advice to stop smoking by physician.
Psychosocial intervention: information about the effects of smoking by physician and nurse, reinforced by a
booklet about coronary-risk factors. Continued in follow-up clinic and through a community nurse.
(Specific, Intensity 5)
Outcomes Follow-up at 12 months (abstinence self-report)
Notes IG: OM = 63.2%
CG: OM = 27.5%
Allocation concealment C – Inadequate
Study CASIS 1992
Methods OM, ITT
Participants 267 smokers with CAD of 3 hospitals who scheduled for coronary arteriography
IG: 135 smokers
CG: 132 smokers
Interventions Usual care: brief advice from physician to stop smoking.
Psychosocial intervention: interventionprovided by trained behaviourally oriented health educators: inpatient
counselling session (30 min), outpatient counselling visits and telephone calls (at 1and 3 weeks, abstinent
smokers at 3 months, relapsed smokers at 2 and 4 months), outpatient group program, self-help materials.
(BT, Ph, SH, Specific, Intensity 4)
Outcomes Follow-up at 6, 12 and 60 months (validation by saliva samples)
Notes IG: OM = 57.3%
ITT = 34.8%
CG: OM = 47.4%
ITT = 28%
Allocation concealment B – Unclear
Study Carlsson 1997
Methods OM
Participants 168 patients with AMI admitted to the coronary care unit at Malmö General Hospital
IG: 32 smokers
CG: 35 smokers
Interventions Usual care: two visits to general practitioner.
Psychosocial intervention: nurse-directed secondary prevention unit after the usual follow-up schedule: edu-
cation and counselling (individual and group sessions) about smoking, exercise, nutrition for about 9 hours
and exercise training 2-3 times per week. Visits to cardiologist after 2, 3, 6 months and to nurse after 3, 5,
6, 9, 12 months.
(MR, Intensity 5)
Outcomes Follow-up at 12 months (abstinence self-report)
Notes IG: OM = 50%
CG: OM = 25.7%
Allocation concealment B – Unclear
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Characteristics of included studies (Continued )
Study DeBusk 1994
Methods OM
Participants 585 patients with AMI in five medical centres
IG: 131 smokers
CG: 120 smokers
Interventions Usual care: counselling on dietary change, lipid lowering therapy, and on demand smoking cessation inter-
ventions.
Psychosocial intervention: physician-directed, nurse-managed, home-based case-management system (be-
havioural intervention, telephone and mail contact) in addition to the usual care. Started in the hospital and
finished 12 months later.
(BT, Ph, SH, MR, Intensity 5)
Outcomes Follow-up at 6 and 12 months (abstinence validated)
Notes IG: OM = 70.2%
CG: OM = 53.3%
Allocation concealment B – Unclear
Study Dornelas 2000
Methods OM, ITT
Participants 100 smokers with AMI admitted to hospital
IG: 54 smokers
CG: 46 smokers
Interventions Usual care: verbal and written recommendation to watch education video of AHA.
Psychosocial intervention: bedside cessation counselling (motivation for cessation, relapse prevention) deliv-
ered by a psychologist based on the transtheoretical model.
Seven telephone calls at 1, 4, 8, 12, 16, 20, 26 weeks
(BT, Ph, Specific, Intensity 4)
Outcomes Follow-up at 6 and 12 months (validation by a significant other)
Notes IG: OM = 70%
ITT = 51.8%
CG: OM = 40%
ITT = 34.8%
Allocation concealment A – Adequate
Study Hajek 2002
Methods OM, ITT
Participants 540 patients in hospitals in UK with MI and CABG
IG: 274
CG: 266
Interventions Usual care: verbal advice to stop smoking and booklet “Smoking and your heart”.
Psychosocial intervention: in 17 hospitals patients motivated to stop smoking received intervention. Educa-
tion with booklet (Smoking and your Heart) from the British Heart Foundation. Short quiz on contents of
the booklet; support of other cardiac patient is arranged by nurse Duration about 34min
(SH, Specific, Intensity 1)
Outcomes Follow-up at 6 weeks and 12 months (validated)
Notes IG: OM = 39%
ITT = 36%
CG: OM = 43%
ITT = 41%
15Psychosocial interventions for smoking cessation in patients with coronary heart disease (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Characteristics of included studies (Continued )
Allocation concealment A – Adequate
Study Heller 1993
Methods OM
Participants 450 patients with AMI discharged from the hospital
IG: 66 smokers
CG: 73 smokers
Interventions Usual care: no specific information given
Psychosocial intervention: letter to the subjects’ GP, three mail-out packages for the subjects (information
about nutrition, smoking, walking programme) and monthly newsletters.
(SH, MR, Intensity 1)
Outcomes Follow-up at 6 months (abstinence self-report)
Notes IG: OM = 65%
CG: OM = 53%
Allocation concealment C – Inadequate
Study Ortigosa 2000
Methods OM, ITT
Participants 90 patients with myocardial infarction in hospital in Spain
IG: 43 smokers
CG: 47 smokers
Interventions Usual care: advice only.
Psychosocial intervention: advice by doctor immediately after admission to hospital (10 minutes). Additional
enhancement of motivation by nurses and phone contacts (after 2, 3, 4 weeks).
(Ph, Specific, Intensity 3)
Outcomes Follow-up at 1, 3 and 12 months (validated)
Notes IG: OM = 62%
ITT = 61%
CG: OM = 69%
ITT = 66%
Allocation concealment B – Unclear
Study Quist-Paulsen 2003
Methods OM, ITT
Participants Patients in hospital (reasons myocardial infarction, angina pectoris, coronary artery bypass surgery)
IG: 118 smokers
CG: 122 smokers
Interventions Usual care: no specific intervention.
Psychosocial intervention: group intervention with nurses (twice a week). Booklet with emphasis on health
benefits from smoking cessation. Also fear arousing message about death rates of persistent smokers. Advice
not to smoke during hospital stay and motivation for NRT if needed additional phone contacts (5 times) in
5 months after hospital stay.
(BT, Ph, SH, Specific, Intensity 4)
Outcomes Follow-up 12 months (validated)
Notes IG: OM = 57%
ITT = 48%
CG: OM = 37%
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Characteristics of included studies (Continued )
ITT = 36%
Allocation concealment B – Unclear
Study Reid 2003
Methods ITT
Participants Patients in hospital in Canada (reasons: angiography, PTCA, Myocardial infarction, coronary artery bypass
surgery.
IG: 126 smokers
CG: 128 smokers
Interventions Usual care: no additional intervention after discharge.
Psychosocial intervention: assessment of smoking status after 4 weeks. Abstinent patients were reinforced.
Those still smoking were offered support by nurse (3 sessions with 20minutes in 8 weeks) and additionally
nicotine patch therapy
(BT, Ph, SH, Specific, Intensity 4)
Outcomes Follow-up at 3 and 12 months (not validated self-report)
Notes IG: ITT = 39%
CG: ITT = 36%
Allocation concealment A – Adequate
Study Rigotti 1994
Methods ITT
Participants 93 patients (smokers) scheduled for CABS in the postoperative cardiac surgery unit at Massachusetts General
Hospital
IG: 44 smokers
CG: 43 smokers
Interventions Usual care: Brief advice not to smoke within a group session.
Psychosocial intervention:
Nurse-based smoking cessation and relapse prevention programme adapted from the American Lung As-
sociation’s “In Control” programme: three-counselling sessions, videotape, family members were included.
Phone call 1 week after discharge by nurse.
(BT, Ph, SH, Specific, Intensity 3)
Outcomes Follow-up at 2, 4, 8, 12 months and 5 years (validation by saliva cotinine)
Notes IG: ITT = 43%
CG: ITT = 44%
Allocation concealment B – Unclear
Study Sivarajan 1983
Methods OM, ITT
Participants 258 patients hospitalised with AMI
IG1: 43 smokers
IG2: 39 smokers
CG: 37 smokers
Interventions Usual care: conventional medical and nursing management.
Psychosocial intervention: two intervention groups - EG1: exercise only (for 12 weeks, weekly clinic visits);
EG2: exercise, teaching and counselling ( 8 group sessions about risk factors, diet, exercise, stress management
etc, individual counselling if needed). Data only of EG 2 used for analysis.
(BT, SH, MR, Intensity 4)
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Characteristics of included studies (Continued )
Outcomes Follow-up at 3 and 6 months (abstinence self-report)
Notes IG: OM = 48%
ITT = 33%
CG: OM = 58%
ITT = 37%
Allocation concealment B – Unclear
Study Taylor 1990
Methods OM
Participants 173 patients (smokers) admitted to hospital with AMI
IG: 72 smokers
CG: 58 smokers
Interventions Usual care: no specific instruction to stop smoking. 10% participated in non smoking classes.
Psychosocial intervention: nurse-managed intervention based on social learning theory: manual “Staying
Free”, 2 audio tapes for relaxation. Telephone contact after discharge (6 times), counselling after relapse.
(BT, Ph, SH, Specific, Intensity 4)
Outcomes Follow-up at 6 and 12 months (biochemical validation)
Notes IG: OM = 70%
CG: OM = 44%
Allocation concealment A – Adequate
Study van Elderen (group)
Methods OM
Participants Of 477 patients with CHD after discharge from hospital 258 were included.
Diagnosis: MI (144), CABS (42), PTCA (10), other (21)
IG: 64 smokers
CG: 64 smokers
Interventions Usual care: standard rehabilitation with medical care and physical training.
Psychosocial intervention: health education programme “Heart and Health” based on Ellis’ Rational Emotive
Therapy (ABCDE model): information about heart disease, risks, diet, exercise, identification and modifi-
cation of irrational beliefs.
8 weekly group sessions (2h) for the patients and their partners, one follow-up session at 2 months.
(BT, MR, Intensity 4)
Outcomes Follow-up at 3 and 12 months (abstinence self-report)
Notes IG: OM = 62%
CG: OM = 50%
Allocation concealment B – Unclear
Study van Elderen (phone)
Methods OM
Participants 60 patients admitted to hospital with AMI
IG: 15 smokers
CG: 16 smokers
Interventions Usual care: standard medical care.
Psychosocial intervention: health education and counselling programme: two nurse-based counselling ses-
sions, two group health education sessions (medication, aetiology of MI, risk factors, anxiety, depression etc).
Weekly telephone contacts by nurse after discharge for 6 weeks.
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(Ph, SH, MR, Intensity 4)
Outcomes Follow-up after intervention, at 8 weeks and 1 year (abstinence self-report)
Notes IG: OM = 60%
CG: OM = 37%
Allocation concealment B – Unclear
OM= optimistic model; ITT = intent to treat analysis; CABG = coronary artery bypass surgery; CAD = coronary artery disease; AMI = acute myocardial
infarction; CG = control group; IG = experimental intervention group; GP = general practitioner
Duration of treatment is coded as follows (intensity):
coding 1: single initial contact lasting <= 1 hour, no follow-up support
coding 2: one or more contacts in total > 1 hour, no follow-up support
coding 3: any initial contact plus follow-up <=1 month
coding 4: any initial contact plus follow-up > 1 month and <= 6 month
coding 5: any initial contact plus follow-up > 6 month.
Number in notes section show abstince rates in percent
Characteristics of excluded studies
Study Reason for exclusion
Andersen 2002 Patients with other disease, or healthy subjects
Baughman 1982 No intervention specified or no specific smoking cessation intervention
Belson 2002 Heterogeneity in diagnosis included / no assessment of smoking status
Bolman 2002 Follow up too short
Brenner 1989 No intervention specified or no specific smoking cessation intervention / no assessment of smoking status
Byfield 2001 Patients with other disease, or healthy subjects / no assessment of smoking status
Campbell 1996 Heterogeneity in diagnosis included
Campbell 1998a No clear diagnosis of CHD
Campbell 1998b No clear diagnosis of CHD
Circo 1985 Follow up too short
Connett 1984 No information about diagnosis included
Cook 1989 No data reported
Cupples 1999 Patients with other heart disease
Eaker 1982 Patients with other disease, or healthy subjects
Engblom 1992 no intervention specified or no specific smoking cessation intervention
Erdman 1983 No intervention specified or no specific smoking cessation intervention
Feeney 2001 Drop out > 50%
Finnegan 1985 Cross sectional analysis, not sufficient data / no intervention specified or no specific smoking cessation inter-
vention
Fletcher 1987 No intervention specified or no specific smoking cessation intervention / no comparison of smoking status
feasible
Fortmann 1994 No intervention specified or no specific smoking cessation intervention / no comparison of usual care and
specific psychosocial intervention
Frasure-Smith 1997 No comparison of smoking status feasible
Fredrickson 1995 Patients with other disease, or healthy subjects / no intervention specified or no specific smoking cessation
intervention / follow up too short
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Hall 1983 Heterogeneity in diagnosis included
Haskell 1994 No possibility to include data in meta-analysis
Hjermann 1986 Heterogeneity in diagnosis included
Horlick 1984 No comparison of smoking status feasible
Houston-Miller 1997 Heterogeneity in diagnosis included
Jones 1996 No intervention specified or no specific smoking cessation intervention / no assessment of smoking status
Joseph 1996 No intervention specified or no specific smoking cessation intervention
Kallio 1981 Follow up too short
Knutsen 1991 Patients with other disease, or healthy subjects
Kornitzer 1980 Patients with other disease, or healthy subjects
Kornitzer 1989 Patients with other disease, or healthy subjects / no comparison of smoking status feasible
Kristeller 1993 No comparison of smoking status feasible
Kuller 1991 Heterogeneity in diagnosis included / no intervention specified or no specific smoking cessation intervention
Lancaster 1999 Patients with other disease, or healthy subjects
Lisspers 1999 Assessment of smoking status was made after cardiac procedure had been performed
Marra 1985 No intervention specified or no specific smoking cessation intervention
Mayou 2002 No intervention specified or no specific smoking cessation intervention / no comparison of smoking status
feasible
McHugh 2001 No assessment of smoking status
Meland 1999 Cross sectional analysis, not sufficient data
Mitsibounas 1992 Statistically significant difference in patient characteristics at baseline between intervention and control groups
Murchie 2003 No clear diagnosis of CHD
Nisbeth 2000 Patients with other disease, or healthy subjects
Ornish 1990 No comparison of smoking status feasible / no assessment of smoking status
Patel 1985 No information about diagnosis included / no comparison of smoking status feasible
Prieme 1998 Patients with other disease, or healthy subjects / cross sectional analysis, not sufficient data /no intervention
specified or no specific smoking cessation intervention / no assessment of smoking status
Rice 1994 Heterogeneity in diagnosis included
Risser 1990 Patients with other disease, or healthy subjects
Rose 1978 Patients with other disease, or healthy subjects
Rose 1982 Patients with other disease, or healthy subjects
Rose 1992 Patients with other disease, or healthy subjects
Sanders 1989 No information about diagnosis included
Schmitz 1999 No comparison of usual care and specific psychosocial intervention
Simon 2003 Heterogeneity in diagnosis included
Sippel 1999 Heterogeneity in diagnosis included
Steptoe 1999 Other heart diseases / patients with other disease, or healthy subjects
Steptoe 2001 Other heart diseases / patients with other disease, or healthy subjects
Stewart 1999 Other heart diseases / no intervention specified or no specific smoking cessation intervention
Suurkula 1996 Heterogeneity in diagnosis included
Taylor 1988 No intervention specified or no specific smoking cessation intervention
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Characteristics of excluded studies (Continued )
Taylor 1997 No assessment of smoking status
Tiffany 1986 Patients with other disease, or healthy subjects
Tonnesen 1999 Other heart diseases
Tonstad 2003 Heterogeneity in diagnosis included / no intervention specified or no specific smoking cessation intervention
Toobert 1998 No comparison of smoking status feasible
Toobert 2000 No comparison of smoking status feasible
Tzivoni 1998 Cross sectional analysis, not sufficient data /no intervention specified or no specific smoking cessation inter-
vention
Vedin 1976 No intervention specified or no specific smoking cessation intervention
Wallner 1999 No intervention specified or no specific smoking cessation intervention / no assessment of smoking status
Waters 1996 No intervention specified or no specific smoking cessation intervention
Wewers 1994 Heterogeneity in diagnosis included
Whitlock 1997 Heterogeneity in diagnosis included / no information about diagnosis included
A D D I T I O N A L T A B L E S
Table 01. EMBASE search strategy
#1 HEART DISEASES (exp MeSH)
#2 CORONARY ARTERY BYPASS (exp MeSH)
#3 angina*
#4 cabg
#5 (coronary near bypass*)
#6 (coronary near disease*)
#7 MYOCARDIAL INFARCTION (exp MeSH)
#8 (myocard* near infarct*)
#9 (heart near infarct*)
#10 chd
#11 (heart next disease*)
#12 (cardiac next disease*)
#13 acs
#14 ami
#15 (cardiac next inpatient*)
#16 (cardiac next patient*)
#17 (heart next patient*)
#18 (heart next inpatient*)
#19 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)
#20 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18)
#21 (#19 or #20)
#22 SMOKING CESSATION (exp MeSH)
#23 (smoking near cessation)
#24 (smoking near cease*)
#25 (smoking near quit*)
#26 antismoking
#27 (anti next smoking)
#28 (smoking near giv*)
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Table 01. EMBASE search strategy (Continued )
#29 (smoking near stop*)
#30 (#22 or #23 or #24 or #25 or #26 or #27 or #28 or #29)
#31 (#21 and #30)
Table 02. Search strategy for MEDLINE, Pre-MEDLINE, BIOSIS and Journals@Ovid
#1 (HEART DISEASES ) in KW,MESH,PS (44527 records)
#2 (coronary artery bypass) in KW,MESH,PS (25318 records)
#3 angina* (40369 records)
#4 cabg (5015 records)
#5 coronary near bypass (32268 records)
#6 coronary near disease (124131 records)
#7 (myocardial infarction) in KW,MESH,PS (87348 records)
#8 myocard* near infarct* (109488 records)
#9 heart near infarct* (10780 records)
#10 chd (6501 records)
#11 heart next disease* (113611 records)
#12 acs (2061 records)
#13 ami (6556 records)
#14 cardiac next inpatient* (54 records)
#15 cardiac next patient* (11097 records)
#16 heart next patient* (10654 records)
#17 heart next inpatient* (10 records)
#18 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 (322389 records)
#19 (smoking cessation) in KW,MESH,PS (6284 records)
#20 smoking near cease* (87 records)
#21 smoking near cessation (9035 records)
#22 smoking near quit (1849 records)
#23 antismoking (329 records)
#24 anti next smoking (464 records)
#25 smoking near giv* (1106 records)
#26 smoking near stop* (2067 records)
#27 #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 (11672 records)
#28 #18 and #27 (1181 records)
Table 03. Search strategy for PsycINFO
#1 TI coronary artery bypass Or AB coronary artery bypass Or MJ coronary artery bypass
#2 TI angina Or AB angina Or MJ angina
#3 TI cabg Or AB cabg Or MJ cabg
#4 TI coronary Or AB coronary Or MJ coronary
#5 TI bypass Or AB bypass Or MJ bypass
#6 TI myocard Or AB myocard Or MJ myocard
#7 TI myocard Or AB myocard Or MJ myocard
#8 TI diseas* Or AB diseas*Or MJ diseas*
#9 TI heart* Or AB heart* Or MJ heart*
#10 TI chd Or AB chd Or MJ chd
#11 TI acs Or AB acs Or MJ acs
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Table 03. Search strategy for PsycINFO (Continued )
#12 TI ami Or AB ami Or MJ ami
#13 TI cardiac Or AB cardiac Or MJ cardiac
#14 TI patient* Or AB patient* Or MJ patient*
#15 TI inpatient* Or AB inpatient* Or MJ inpatient*
#16 TI smok* Or AB smok* Or MJ smok*
#17 TI cessation Or AB cessation Or MJ cessation
#18 TI cease* Or AB cease* Or MJ cease*
#19 TI quit Or AB quit Or MJ quit*
#20 TI anti Or AB anti Or MJ anti
#21 TI giv* Or AB giv* Or MJ giv*
#22 TI stop* Or AB stop* Or MJ stop*
#23 (S5 And S4)
#24 (S8And S4)
#25 (S7 And S6)
#26 (S9And S7
#27 (S14 And S13)
#28 (S15 And S13)
#29 (S14 And S9)
#30 (S15 And S9)
#31 (S30 Or S29 Or S28 Or S27 Or S26 Or S25 Or S24 Or S23 Or S15 Or S14 Or S13 Or S12 Or S11 Or S10 Or S9 Or S8 Or S7
Or S6 Or S5 Or S4 Or S3 Or S2 Or S1)
#32 (S17 And S16)
#33 (S18 And S16)
#34 (S19 And S16)
#35 (S20 And S16)
#36 (S21 And S16)
#37 (S22 And S16)
#38 (S37 Or S36 Or S35 Or S34 Or S33 Or S32 Or S22 Or S21 Or S20 Or S19 Or S18 Or S17 Or S16)
#39 (S37 Or S36 Or S35 Or S34 Or S33 Or S32)
#40 (S13 Or S12 Or S11 Or S10 Or S9 Or S8 Or S7 Or S6 Or S5 Or S4 Or S3 Or S2 Or S1)
#41 (S39 and S40)
Table 04. Search strategy for PSYNDEXplus
#1 HEART DISEASES
#2 CORONARY ARTERY BYPASS
#3 angina*
#5 coronary near bypass*
#6 coronary near disease*
#7 MYOCARDIAL INFARCTION
#8 myocard* near infarct*
#9 heart near infarct*
#10 chd
#11 heart next disease*
#12 cardiac next disease*
#13 acs
#14 ami
#15 cardiac next inpatient*
#16 cardiac next patient*
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Table 04. Search strategy for PSYNDEXplus (Continued )
#17 heart next patient*
#18 heart next inpatient*
#19 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 SMOKING CESSATION
#21 smoking near cessation
#22 smoking near cease*
#23 smoking near quit*
#24 antismoking
#25 anti next smoking
#26 smoking near giv*
#27 smoking near stop*
#28 #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
#29 herz
#30 herzinfarkt
#31 kardiovaskulaer*
#32 KHK
#33 myokard*
#34 koronar*
#35 bypass
#36 #29 or #30 or #31 or #32 or #33 or #34 or #35
#37 raucherentwoehnung
#38 tabakabstinenz
#39 tabak near abstinenz
#4 cabg
#40 rauchen near abstinenz
#41 rauchen near aufhoeren
#42 #37 or #38 or #39 or #40 or #41
#43 #19 or #36
#44 #28 or #42
#45 #43 and #44
A N A L Y S E S
Comparison 01. Efficacy of psychosocial interventions on abstinence (6 to 12 months; all trials)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Abstinence 6 to 12 months
(ITT preferred and OM)
16 2677 Odds Ratio (Random) 95% CI 1.66 [1.25, 2.22]
02 Abstinence 6 to 12 months
(ITT preferred and OM)
4 919 Odds Ratio (Random) 95% CI 1.10 [0.75, 1.60]
03 Abstinence 6 to 12 months
(ITT only)
11 2215 Odds Ratio (Random) 95% CI 1.47 [1.10, 1.96]
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Comparison 02. Sensitivity analysis validation (abstinence 6 to 12 months)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Abstinence at 6 to 12 months 16 2677 Odds Ratio (Random) 95% CI 1.66 [1.25, 2.22]
Comparison 03. Grouped by type of intervention (6 to 12 months)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Abstinence 6 to 12 months
BEHAVIORAL THERAPY
16 2677 Odds Ratio (Random) 95% CI 1.66 [1.25, 2.22]
02 Abstinence 6 to 12 months
TELEPHONE SUPPORT
16 2677 Odds Ratio (Random) 95% CI 1.66 [1.25, 2.22]
03 Abstinence 6 to 12 months
SELF HELP MATERIALS
16 2677 Odds Ratio (Random) 95% CI 1.66 [1.25, 2.22]
04 Abstinence 6 to 12 months
Specific vs. Multi-Risk-Factor
Intervention
16 2677 Odds Ratio (Random) 95% CI 1.66 [1.25, 2.22]
Comparison 04. Sensitivity analysis brief / intense intervention (6 to 12 months)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Abstinence 6 to 12 months all
studies
16 2677 Odds Ratio (Random) 95% CI 1.66 [1.25, 2.22]
Comparison 05. Efficacy of psychosocial interventions on long term abstinence (five years)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Abstinence five years (OM
only)
2 226 Odds Ratio (Random) 95% CI 1.32 [0.78, 2.24]
02 Abstinence five years (ITT
only)
2 348 Odds Ratio (Random) 95% CI 1.23 [0.79, 1.93]
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Analysis 01.01. Comparison 01 Efficacy of psychosocial interventions on abstinence (6 to 12 months; all
trials), Outcome 01 Abstinence 6 to 12 months (ITT preferred and OM)
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 01 Efficacy of psychosocial interventions on abstinence (6 to 12 months; all trials)
Outcome: 01 Abstinence 6 to 12 months (ITT preferred and OM)
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
Allen 1996 9/14 6/11 2.4 1.50 [ 0.30, 7.53 ]
Burt 1974 79/125 27/98 7.5 4.52 [ 2.55, 8.01 ]
Carlsson 1997 16/32 9/35 4.5 2.89 [ 1.03, 8.07 ]
CASIS 1992 47/135 34/132 7.9 1.54 [ 0.91, 2.61 ]
DeBusk 1994 78/131 57/121 8.1 1.65 [ 1.00, 2.72 ]
Dornelas 2000 28/54 16/46 5.8 2.02 [ 0.90, 4.53 ]
Hajek 2002 99/274 108/266 9.3 0.83 [ 0.58, 1.17 ]
Heller 1993 34/52 38/64 6.1 1.29 [ 0.61, 2.76 ]
Ortigosa 2000 26/43 31/47 5.5 0.79 [ 0.33, 1.86 ]
Quist-Paulsen 2003 57/118 44/122 8.0 1.66 [ 0.99, 2.78 ]
Reid 2003 49/126 46/128 8.0 1.13 [ 0.68, 1.89 ]
Rigotti 1994 27/44 23/43 5.5 1.38 [ 0.59, 3.24 ]
Sivarajan 1983 13/39 14/37 5.0 0.82 [ 0.32, 2.10 ]
Taylor 1990 51/86 26/87 7.1 3.42 [ 1.82, 6.41 ]
van Elderen (group) 46/66 32/70 6.5 2.73 [ 1.35, 5.53 ]
van Elderen (phone) 9/15 6/16 2.9 2.50 [ 0.59, 10.62 ]
Total (95% CI) 1354 1323 100.0 1.66 [ 1.25, 2.22 ]
Total events: 668 (Treatment), 517 (Control)
Test for heterogeneity chi-square=42.68 df=15 p=0.0002 I² =64.9%
Test for overall effect z=3.48 p=0.0005
0.1 0.2 0.5 1 2 5 10
Favours usual care Favours treatment
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Analysis 01.02. Comparison 01 Efficacy of psychosocial interventions on abstinence (6 to 12 months; all
trials), Outcome 02 Abstinence 6 to 12 months (ITT preferred and OM)
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 01 Efficacy of psychosocial interventions on abstinence (6 to 12 months; all trials)
Outcome: 02 Abstinence 6 to 12 months (ITT preferred and OM)
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
Allen 1996 9/14 6/11 5.1 1.50 [ 0.30, 7.53 ]
Dornelas 2000 28/54 16/46 17.0 2.02 [ 0.90, 4.53 ]
Hajek 2002 99/274 108/266 46.0 0.83 [ 0.58, 1.17 ]
Reid 2003 49/126 46/128 31.9 1.13 [ 0.68, 1.89 ]
Total (95% CI) 468 451 100.0 1.10 [ 0.75, 1.60 ]
Total events: 185 (Treatment), 176 (Control)
Test for heterogeneity chi-square=4.52 df=3 p=0.21 I² =33.6%
Test for overall effect z=0.48 p=0.6
0.1 0.2 0.5 1 2 5 10
Favours usual care Favours treatment
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Analysis 01.03. Comparison 01 Efficacy of psychosocial interventions on abstinence (6 to 12 months; all
trials), Outcome 03 Abstinence 6 to 12 months (ITT only)
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 01 Efficacy of psychosocial interventions on abstinence (6 to 12 months; all trials)
Outcome: 03 Abstinence 6 to 12 months (ITT only)
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
CASIS 1992 47/135 34/132 10.5 1.54 [ 0.91, 2.61 ]
DeBusk 1994 78/131 57/121 10.9 1.65 [ 1.00, 2.72 ]
Dornelas 2000 28/54 16/46 7.2 2.02 [ 0.90, 4.53 ]
Hajek 2002 99/274 108/266 13.1 0.83 [ 0.58, 1.17 ]
Ortigosa 2000 26/43 31/47 6.7 0.79 [ 0.33, 1.86 ]
Quist-Paulsen 2003 57/118 44/122 10.7 1.66 [ 0.99, 2.78 ]
Reid 2003 49/126 46/128 10.8 1.13 [ 0.68, 1.89 ]
Rigotti 1994 27/44 23/43 6.7 1.38 [ 0.59, 3.24 ]
Sivarajan 1983 13/39 14/37 6.0 0.82 [ 0.32, 2.10 ]
Taylor 1990 51/86 26/87 9.2 3.42 [ 1.82, 6.41 ]
van Elderen (group) 46/66 32/70 8.3 2.73 [ 1.35, 5.53 ]
Total (95% CI) 1116 1099 100.0 1.47 [ 1.10, 1.96 ]
Total events: 521 (Treatment), 431 (Control)
Test for heterogeneity chi-square=25.27 df=10 p=0.005 I² =60.4%
Test for overall effect z=2.59 p=0.01
0.1 0.2 0.5 1 2 5 10
Favours usual care Favours treatment
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Analysis 02.01. Comparison 02 Sensitivity analysis validation (abstinence 6 to 12 months), Outcome 01
Abstinence at 6 to 12 months
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 02 Sensitivity analysis validation (abstinence 6 to 12 months)
Outcome: 01 Abstinence at 6 to 12 months
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
01 no validation
Allen 1996 9/14 6/11 2.4 1.50 [ 0.30, 7.53 ]
Burt 1974 79/125 27/98 7.5 4.52 [ 2.55, 8.01 ]
Carlsson 1997 16/32 9/35 4.5 2.89 [ 1.03, 8.07 ]
Dornelas 2000 28/54 16/46 5.8 2.02 [ 0.90, 4.53 ]
Heller 1993 34/52 38/64 6.1 1.29 [ 0.61, 2.76 ]
Reid 2003 49/126 46/128 8.0 1.13 [ 0.68, 1.89 ]
Sivarajan 1983 13/39 14/37 5.0 0.82 [ 0.32, 2.10 ]
van Elderen (group) 46/66 32/70 6.5 2.73 [ 1.35, 5.53 ]
van Elderen (phone) 9/15 6/16 2.9 2.50 [ 0.59, 10.62 ]
Subtotal (95% CI) 523 505 48.8 1.92 [ 1.26, 2.93 ]
Total events: 283 (Treatment), 194 (Control)
Test for heterogeneity chi-square=18.64 df=8 p=0.02 I² =57.1%
Test for overall effect z=3.05 p=0.002
02 validation
CASIS 1992 47/135 34/132 7.9 1.54 [ 0.91, 2.61 ]
DeBusk 1994 78/131 57/121 8.1 1.65 [ 1.00, 2.72 ]
Hajek 2002 99/274 108/266 9.3 0.83 [ 0.58, 1.17 ]
Ortigosa 2000 26/43 31/47 5.5 0.79 [ 0.33, 1.86 ]
Quist-Paulsen 2003 57/118 44/122 8.0 1.66 [ 0.99, 2.78 ]
Rigotti 1994 27/44 23/43 5.5 1.38 [ 0.59, 3.24 ]
Taylor 1990 51/86 26/87 7.1 3.42 [ 1.82, 6.41 ]
Subtotal (95% CI) 831 818 51.2 1.44 [ 0.99, 2.11 ]
Total events: 385 (Treatment), 323 (Control)
Test for heterogeneity chi-square=18.96 df=6 p=0.004 I² =68.4%
Test for overall effect z=1.91 p=0.06
Total (95% CI) 1354 1323 100.0 1.66 [ 1.25, 2.22 ]
Total events: 668 (Treatment), 517 (Control)
Test for heterogeneity chi-square=42.68 df=15 p=0.0002 I² =64.9%
Test for overall effect z=3.48 p=0.0005
0.1 0.2 0.5 1 2 5 10
Favours usual care Favours treatment
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Analysis 03.01. Comparison 03 Grouped by type of intervention (6 to 12 months), Outcome 01 Abstinence 6
to 12 months BEHAVIORAL THERAPY
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 03 Grouped by type of intervention (6 to 12 months)
Outcome: 01 Abstinence 6 to 12 months BEHAVIORAL THERAPY
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
01 Behavioral therapeutic approach
Allen 1996 9/14 6/11 2.4 1.50 [ 0.30, 7.53 ]
CASIS 1992 47/135 34/132 7.9 1.54 [ 0.91, 2.61 ]
DeBusk 1994 78/131 57/121 8.1 1.65 [ 1.00, 2.72 ]
Dornelas 2000 28/54 16/46 5.8 2.02 [ 0.90, 4.53 ]
Quist-Paulsen 2003 57/118 44/122 8.0 1.66 [ 0.99, 2.78 ]
Reid 2003 49/126 46/128 8.0 1.13 [ 0.68, 1.89 ]
Rigotti 1994 27/44 23/43 5.5 1.38 [ 0.59, 3.24 ]
Sivarajan 1983 13/39 14/37 5.0 0.82 [ 0.32, 2.10 ]
Taylor 1990 51/86 26/87 7.1 3.42 [ 1.82, 6.41 ]
van Elderen (group) 46/66 32/70 6.5 2.73 [ 1.35, 5.53 ]
Subtotal (95% CI) 813 797 64.2 1.69 [ 1.33, 2.14 ]
Total events: 405 (Treatment), 298 (Control)
Test for heterogeneity chi-square=11.77 df=9 p=0.23 I² =23.5%
Test for overall effect z=4.28 p=0.00002
02 No behavioral therapeutic approach
Burt 1974 79/125 27/98 7.5 4.52 [ 2.55, 8.01 ]
Carlsson 1997 16/32 9/35 4.5 2.89 [ 1.03, 8.07 ]
Hajek 2002 99/274 108/266 9.3 0.83 [ 0.58, 1.17 ]
Heller 1993 34/52 38/64 6.1 1.29 [ 0.61, 2.76 ]
Ortigosa 2000 26/43 31/47 5.5 0.79 [ 0.33, 1.86 ]
van Elderen (phone) 9/15 6/16 2.9 2.50 [ 0.59, 10.62 ]
Subtotal (95% CI) 541 526 35.8 1.68 [ 0.83, 3.39 ]
Total events: 263 (Treatment), 219 (Control)
Test for heterogeneity chi-square=29.00 df=5 p=<0.0001 I² =82.8%
Test for overall effect z=1.44 p=0.2
Total (95% CI) 1354 1323 100.0 1.66 [ 1.25, 2.22 ]
Total events: 668 (Treatment), 517 (Control)
Test for heterogeneity chi-square=42.68 df=15 p=0.0002 I² =64.9%
Test for overall effect z=3.48 p=0.0005
0.1 0.2 0.5 1 2 5 10
Favours usual care Favours treatment
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Analysis 03.02. Comparison 03 Grouped by type of intervention (6 to 12 months), Outcome 02 Abstinence 6
to 12 months TELEPHONE SUPPORT
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 03 Grouped by type of intervention (6 to 12 months)
Outcome: 02 Abstinence 6 to 12 months TELEPHONE SUPPORT
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
01 Telephone support
Allen 1996 9/14 6/11 2.4 1.50 [ 0.30, 7.53 ]
CASIS 1992 47/135 34/132 7.9 1.54 [ 0.91, 2.61 ]
DeBusk 1994 78/131 57/121 8.1 1.65 [ 1.00, 2.72 ]
Dornelas 2000 28/54 16/46 5.8 2.02 [ 0.90, 4.53 ]
Heller 1993 34/52 38/64 6.1 1.29 [ 0.61, 2.76 ]
Ortigosa 2000 26/43 31/47 5.5 0.79 [ 0.33, 1.86 ]
Quist-Paulsen 2003 57/118 44/122 8.0 1.66 [ 0.99, 2.78 ]
Reid 2003 49/126 46/128 8.0 1.13 [ 0.68, 1.89 ]
Rigotti 1994 27/44 23/43 5.5 1.38 [ 0.59, 3.24 ]
Taylor 1990 51/86 26/87 7.1 3.42 [ 1.82, 6.41 ]
van Elderen (phone) 9/15 6/16 2.9 2.50 [ 0.59, 10.62 ]
Subtotal (95% CI) 818 817 67.2 1.58 [ 1.28, 1.97 ]
Total events: 415 (Treatment), 327 (Control)
Test for heterogeneity chi-square=11.10 df=10 p=0.35 I² =9.9%
Test for overall effect z=4.17 p=0.00003
02 No telephone support
Burt 1974 79/125 27/98 7.5 4.52 [ 2.55, 8.01 ]
Carlsson 1997 16/32 9/35 4.5 2.89 [ 1.03, 8.07 ]
Hajek 2002 99/274 108/266 9.3 0.83 [ 0.58, 1.17 ]
Sivarajan 1983 13/39 14/37 5.0 0.82 [ 0.32, 2.10 ]
van Elderen (group) 46/66 32/70 6.5 2.73 [ 1.35, 5.53 ]
Subtotal (95% CI) 536 506 32.8 1.88 [ 0.84, 4.23 ]
Total events: 253 (Treatment), 190 (Control)
Test for heterogeneity chi-square=31.35 df=4 p=<0.0001 I² =87.2%
Test for overall effect z=1.52 p=0.1
Total (95% CI) 1354 1323 100.0 1.66 [ 1.25, 2.22 ]
Total events: 668 (Treatment), 517 (Control)
Test for heterogeneity chi-square=42.68 df=15 p=0.0002 I² =64.9%
Test for overall effect z=3.48 p=0.0005
0.1 0.2 0.5 1 2 5 10
Favours usual care Favours treatment
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Analysis 03.03. Comparison 03 Grouped by type of intervention (6 to 12 months), Outcome 03 Abstinence 6
to 12 months SELF HELP MATERIALS
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 03 Grouped by type of intervention (6 to 12 months)
Outcome: 03 Abstinence 6 to 12 months SELF HELP MATERIALS
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
01 SELF HELP MATERIALS provided
Allen 1996 9/14 6/11 2.4 1.50 [ 0.30, 7.53 ]
CASIS 1992 47/135 34/132 7.9 1.54 [ 0.91, 2.61 ]
DeBusk 1994 78/131 57/121 8.1 1.65 [ 1.00, 2.72 ]
Hajek 2002 99/274 108/266 9.3 0.83 [ 0.58, 1.17 ]
Heller 1993 34/52 38/64 6.1 1.29 [ 0.61, 2.76 ]
Quist-Paulsen 2003 57/118 44/122 8.0 1.66 [ 0.99, 2.78 ]
Reid 2003 49/126 46/128 8.0 1.13 [ 0.68, 1.89 ]
Rigotti 1994 27/44 23/43 5.5 1.38 [ 0.59, 3.24 ]
Sivarajan 1983 13/39 14/37 5.0 0.82 [ 0.32, 2.10 ]
Taylor 1990 51/86 26/87 7.1 3.42 [ 1.82, 6.41 ]
van Elderen (group) 46/66 32/70 6.5 2.73 [ 1.35, 5.53 ]
Subtotal (95% CI) 1085 1081 73.8 1.48 [ 1.11, 1.96 ]
Total events: 510 (Treatment), 428 (Control)
Test for heterogeneity chi-square=22.84 df=10 p=0.01 I² =56.2%
Test for overall effect z=2.70 p=0.007
02 No self help materials
Burt 1974 79/125 27/98 7.5 4.52 [ 2.55, 8.01 ]
Carlsson 1997 16/32 9/35 4.5 2.89 [ 1.03, 8.07 ]
Dornelas 2000 28/54 16/46 5.8 2.02 [ 0.90, 4.53 ]
Ortigosa 2000 26/43 31/47 5.5 0.79 [ 0.33, 1.86 ]
van Elderen (phone) 9/15 6/16 2.9 2.50 [ 0.59, 10.62 ]
Subtotal (95% CI) 269 242 26.2 2.24 [ 1.15, 4.36 ]
Total events: 158 (Treatment), 89 (Control)
Test for heterogeneity chi-square=11.35 df=4 p=0.02 I² =64.8%
Test for overall effect z=2.38 p=0.02
Total (95% CI) 1354 1323 100.0 1.66 [ 1.25, 2.22 ]
Total events: 668 (Treatment), 517 (Control)
Test for heterogeneity chi-square=42.68 df=15 p=0.0002 I² =64.9%
Test for overall effect z=3.48 p=0.0005
0.1 0.2 0.5 1 2 5 10
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Analysis 03.04. Comparison 03 Grouped by type of intervention (6 to 12 months), Outcome 04 Abstinence 6
to 12 months Specific vs. Multi-Risk-Factor Intervention
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 03 Grouped by type of intervention (6 to 12 months)
Outcome: 04 Abstinence 6 to 12 months Specific vs. Multi-Risk-Factor Intervention
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
01 Specific smoking cessation intervention
Burt 1974 79/125 27/98 7.5 4.52 [ 2.55, 8.01 ]
CASIS 1992 47/135 34/132 7.9 1.54 [ 0.91, 2.61 ]
Dornelas 2000 28/54 16/46 5.8 2.02 [ 0.90, 4.53 ]
Hajek 2002 99/274 108/266 9.3 0.83 [ 0.58, 1.17 ]
Ortigosa 2000 26/43 31/47 5.5 0.79 [ 0.33, 1.86 ]
Quist-Paulsen 2003 57/118 44/122 8.0 1.66 [ 0.99, 2.78 ]
Reid 2003 49/126 46/128 8.0 1.13 [ 0.68, 1.89 ]
Rigotti 1994 27/44 23/43 5.5 1.38 [ 0.59, 3.24 ]
Taylor 1990 51/86 26/87 7.1 3.42 [ 1.82, 6.41 ]
Subtotal (95% CI) 1005 969 64.5 1.63 [ 1.08, 2.46 ]
Total events: 463 (Treatment), 355 (Control)
Test for heterogeneity chi-square=36.02 df=8 p=<0.0001 I² =77.8%
Test for overall effect z=2.33 p=0.02
02 Multicomponent intervention
Allen 1996 9/14 6/11 2.4 1.50 [ 0.30, 7.53 ]
Carlsson 1997 16/32 9/35 4.5 2.89 [ 1.03, 8.07 ]
DeBusk 1994 78/131 57/121 8.1 1.65 [ 1.00, 2.72 ]
Heller 1993 34/52 38/64 6.1 1.29 [ 0.61, 2.76 ]
Sivarajan 1983 13/39 14/37 5.0 0.82 [ 0.32, 2.10 ]
van Elderen (group) 46/66 32/70 6.5 2.73 [ 1.35, 5.53 ]
van Elderen (phone) 9/15 6/16 2.9 2.50 [ 0.59, 10.62 ]
Subtotal (95% CI) 349 354 35.5 1.73 [ 1.27, 2.35 ]
Total events: 205 (Treatment), 162 (Control)
Test for heterogeneity chi-square=5.86 df=6 p=0.44 I² =0.0%
Test for overall effect z=3.51 p=0.0004
Total (95% CI) 1354 1323 100.0 1.66 [ 1.25, 2.22 ]
Total events: 668 (Treatment), 517 (Control)
Test for heterogeneity chi-square=42.68 df=15 p=0.0002 I² =64.9%
Test for overall effect z=3.48 p=0.0005
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Analysis 04.01. Comparison 04 Sensitivity analysis brief / intense intervention (6 to 12 months), Outcome 01
Abstinence 6 to 12 months all studies
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 04 Sensitivity analysis brief / intense intervention (6 to 12 months)
Outcome: 01 Abstinence 6 to 12 months all studies
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
01 brief intervention
Hajek 2002 99/274 108/266 9.3 0.83 [ 0.58, 1.17 ]
Heller 1993 34/52 38/64 6.1 1.29 [ 0.61, 2.76 ]
Ortigosa 2000 26/43 31/47 5.5 0.79 [ 0.33, 1.86 ]
Rigotti 1994 27/44 23/43 5.5 1.38 [ 0.59, 3.24 ]
Subtotal (95% CI) 413 420 26.4 0.92 [ 0.70, 1.22 ]
Total events: 186 (Treatment), 200 (Control)
Test for heterogeneity chi-square=2.12 df=3 p=0.55 I² =0.0%
Test for overall effect z=0.55 p=0.6
02 high intensity intervention
Allen 1996 9/14 6/11 2.4 1.50 [ 0.30, 7.53 ]
Burt 1974 79/125 27/98 7.5 4.52 [ 2.55, 8.01 ]
Carlsson 1997 16/32 9/35 4.5 2.89 [ 1.03, 8.07 ]
CASIS 1992 47/135 34/132 7.9 1.54 [ 0.91, 2.61 ]
DeBusk 1994 78/131 57/121 8.1 1.65 [ 1.00, 2.72 ]
Dornelas 2000 28/54 16/46 5.8 2.02 [ 0.90, 4.53 ]
Quist-Paulsen 2003 57/118 44/122 8.0 1.66 [ 0.99, 2.78 ]
Reid 2003 49/126 46/128 8.0 1.13 [ 0.68, 1.89 ]
Sivarajan 1983 13/39 14/37 5.0 0.82 [ 0.32, 2.10 ]
Taylor 1990 51/86 26/87 7.1 3.42 [ 1.82, 6.41 ]
van Elderen (group) 46/66 32/70 6.5 2.73 [ 1.35, 5.53 ]
van Elderen (phone) 9/15 6/16 2.9 2.50 [ 0.59, 10.62 ]
Subtotal (95% CI) 941 903 73.6 1.98 [ 1.49, 2.65 ]
Total events: 482 (Treatment), 317 (Control)
Test for heterogeneity chi-square=22.15 df=11 p=0.02 I² =50.3%
Test for overall effect z=4.65 p<0.00001
Total (95% CI) 1354 1323 100.0 1.66 [ 1.25, 2.22 ]
Total events: 668 (Treatment), 517 (Control)
Test for heterogeneity chi-square=42.68 df=15 p=0.0002 I² =64.9%
Test for overall effect z=3.48 p=0.0005
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Analysis 05.01. Comparison 05 Efficacy of psychosocial interventions on long term abstinence (five years),
Outcome 01 Abstinence five years (OM only)
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 05 Efficacy of psychosocial interventions on long term abstinence (five years)
Outcome: 01 Abstinence five years (OM only)
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
CASIS 1992 47/82 37/78 70.7 1.49 [ 0.80, 2.78 ]
Rigotti 1994 15/33 15/33 29.3 1.00 [ 0.38, 2.64 ]
Total (95% CI) 115 111 100.0 1.32 [ 0.78, 2.24 ]
Total events: 62 (Treatment), 52 (Control)
Test for heterogeneity chi-square=0.46 df=1 p=0.50 I² =0.0%
Test for overall effect z=1.05 p=0.3
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Analysis 05.02. Comparison 05 Efficacy of psychosocial interventions on long term abstinence (five years),
Outcome 02 Abstinence five years (ITT only)
Review: Psychosocial interventions for smoking cessation in patients with coronary heart disease
Comparison: 05 Efficacy of psychosocial interventions on long term abstinence (five years)
Outcome: 02 Abstinence five years (ITT only)
Study Treatment Control Odds Ratio (Random) Weight Odds Ratio (Random)
n/N n/N 95% CI (%) 95% CI
CASIS 1992 47/133 37/128 74.2 1.34 [ 0.80, 2.27 ]
Rigotti 1994 15/44 15/43 25.8 0.97 [ 0.40, 2.34 ]
Total (95% CI) 177 171 100.0 1.23 [ 0.79, 1.93 ]
Total events: 62 (Treatment), 52 (Control)
Test for heterogeneity chi-square=0.40 df=1 p=0.53 I² =0.0%
Test for overall effect z=0.92 p=0.4
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